Amylyx Shares Rose 63.84% After Positive Avexitide Phase 3 Results

Trial result drove the session

Amylyx Pharmaceuticals reported on August 18 that avexitide met the FDA-agreed primary endpoint and all reported secondary endpoints in the pivotal Phase 3 LUCIDITY trial for post-bariatric hypoglycemia (PBH). The company reported a 55% reduction versus placebo in the composite rate of Level 2 and Level 3 hypoglycemic events, with a reported p-value of 0.000003. The company release was the principal disclosed catalyst for the stock move.

AMLX closed at $35.11, up $13.68, or 63.84%, from $21.43. Shares traded from $28.00 to $35.39 on volume of 23.98 million shares, and the intraday high set a new 52-week high, according to StockAnalysis market data. The reported closing market capitalization was about $3.91 billion.

Using the reported 111.42 million shares outstanding, the close-to-close increase implies an approximately $1.52 billion increase in equity value. Market data alone cannot establish that the clinical release was the sole cause, though the timing is consistent with a fundamental repricing after the pivotal-trial disclosure.

What LUCIDITY reported

LUCIDITY enrolled 78 adults with PBH following Roux-en-Y gastric bypass at 21 U.S. sites. Participants were randomized 3:2 to 90 mg of subcutaneous avexitide once daily or placebo for 16 weeks. The study is listed as NCT06747468 on ClinicalTrials.gov, which identifies Amylyx as sponsor and gives an estimated overall completion date of October 2026.

Amylyx reported statistically significant results across secondary measures of Level 2 events assessed by self-monitoring and continuous glucose monitoring, along with independently adjudicated Level 3 events. The company also reported that most adverse events were mild or moderate, that no serious adverse events were attributed to avexitide, and that diarrhea, injection-site erythema, and injection-site bruising were the most common events.

These results materially reduce uncertainty over whether avexitide could reproduce earlier efficacy signals in a randomized pivotal trial. The available evidence remains company-reported topline data. The release did not provide complete arm-level event rates, confidence intervals, exact secondary-endpoint effect sizes, adverse-event frequencies, discontinuations, or subgroup analyses.

Approval and commercial questions remain

Amylyx plans to submit a New Drug Application to the Food and Drug Administration by December 31, 2026. Avexitide holds FDA Breakthrough Therapy Designation for PBH and Orphan Drug Designation for hyperinsulinemic hypoglycemia. The 32-week open-label extension and expanded-access program remain ongoing, leaving longer-term efficacy and safety under study.

FDA acceptance of an NDA, review timing, requested analyses, final indication wording, and potential post-marketing requirements remain unknown. Breakthrough Therapy designation supports development and FDA interaction, though it does not assure approval. A possible 2027 launch is conditional on regulatory outcomes.

LUCIDITY studied PBH after Roux-en-Y gastric bypass. Its results do not establish a label that includes patients following sleeve gastrectomy. Amylyx estimates about 160,000 U.S. PBH patients, while Society for Endocrinology guidance says true prevalence is unknown and published estimates vary substantially by diagnostic method.

Amylyx has lacked a marketed product since withdrawing RELYVRIO/ALBRIOZA in 2024 after the Phase 3 PHOENIX ALS study failed its primary and secondary endpoints. Its annual-report disclosures identified avexitide and AMX0035 as programs on which future success depended heavily. The positive trial result therefore changed expectations for Amylyx's potential return to commercial-stage operations.

Financing followed the readout

Amylyx subsequently proposed a $350 million common-stock offering, with an underwriter option for up to $52.5 million more. The company identified avexitide pre-commercial work, added manufacturing capacity, research and development, and general corporate purposes as intended uses in its offering announcement.

At June 30, 2026, Amylyx reported $250.8 million in cash, cash equivalents, and short-term investments, a second-quarter net loss of $43.4 million, and projected runway into 2028. The proposed offering could add resources for launch preparation and manufacturing. Its final price, share count, net proceeds, completion, and resulting dilution were undisclosed in the initial announcement.

MacroShed Markets is informational analysis, not investment advice.